0.3232 USD
+0.0162
5.28%
At close Apr 30, 4:00 PM EDT
After hours
0.3135
-0.0097
3.00%
1 day
5.28%
5 days
9.60%
1 month
6.67%
3 months
28.15%
6 months
-36.65%
Year to date
-27.34%
1 year
-95.15%
5 years
-99.78%
10 years
-99.78%
 

About: Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Employees: 12

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

45% more capital invested

Capital invested by funds: $74.9K [Q3] → $109K (+$34.1K) [Q4]

43% more funds holding

Funds holding: 7 [Q3] → 10 (+3) [Q4]

1.56% more ownership

Funds ownership: 1.8% [Q3] → 3.35% (+1.56%) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for AZTR.

Financial journalist opinion

Neutral
PRNewsWire
5 days ago
Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025
Azitra is developing ATR04-484 for the treatment of EGFR inhibitor-associated rash with plans to dose first patient in Phase 1/2 trial in the first half of 2025 BRANFORD, Conn., April 25, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that an abstract detailing the Phase 1/2 clinical trial of ATR04-484 in EGFR inhibitor ("EGFRi")-associated rash has been accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30-June 3, 2025 in Chicago.
Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025
Neutral
PRNewsWire
6 days ago
Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline
BRANFORD, Conn. , April 24, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has entered into a share purchase agreement (SPA) with Alumni Capital LP (Alumni), an institutional investor.
Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline
Neutral
PRNewsWire
1 month ago
Azitra to Present at Microbiome Times Partnering Forum
BRANFORD, Conn. , March 12, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Chief Operating Officer, Travis Whitfill, Ph.D.
Azitra to Present at Microbiome Times Partnering Forum
Neutral
PRNewsWire
2 months ago
Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates
BRANFORD, Conn. , Feb. 20, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2024, and provided a business update.
Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates
Neutral
PRNewsWire
2 months ago
Azitra Announces Pricing of $930.0 Thousand Registered Direct Offering of Common Stock
BRANFORD, Conn. , Feb. 4, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has entered into a securities purchase agreement with certain institutional investor(s) to purchase 3,339,300 shares of common stock at an offering price of $0.2785 per share, in a registered direct offering.
Azitra Announces Pricing of $930.0 Thousand Registered Direct Offering of Common Stock
Neutral
PRNewsWire
2 months ago
Azitra, Inc. to Present at the BIO CEO & Investor Conference
BRANFORD, Conn. , Feb. 3, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the company will present at the BIO CEO & Investor Conference being held February 10-11, 2025, in New York City.
Azitra, Inc. to Present at the BIO CEO & Investor Conference
Neutral
PRNewsWire
3 months ago
Azitra, Inc. to Present at The Microcap Conference
BRANFORD, Conn. , Jan. 27, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the company will present at The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, NJ.
Azitra, Inc. to Present at The Microcap Conference
Neutral
PRNewsWire
3 months ago
Azitra Announces Pricing of $1.5 Million Public Offering of Common Stock
BRANFORD, Conn. , Jan. 15, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the pricing of its previously announced public offering of 4,857,780 shares of common stock at a public offering price of $0.30 per share.
Azitra Announces Pricing of $1.5 Million Public Offering of Common Stock
Neutral
PRNewsWire
3 months ago
Azitra Announces Proposed Public Offering of Common Stock
BRANFORD, Conn. , Jan. 14, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has commenced a public offering of shares of its common stock (or pre-funded warrants in lieu thereof).
Azitra Announces Proposed Public Offering of Common Stock
Neutral
PRNewsWire
5 months ago
Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates
BRANFORD, Conn. , Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended September 30, 2024 and provided a business update.
Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates
Charts implemented using Lightweight Charts™